Hormonal therapy of endometrial stromal sarcoma

Area of Science:

• Gynecologic Oncology
• Endocrinology
• Pharmacology

Background:

• Low-grade endometrial stromal sarcoma (LG-ESS) is characterized by slow progression, high recurrence rates, and a lack of established treatment protocols.
• These tumors are steroid receptor-positive, indicating a potential role for hormonal manipulation in their management.

Purpose of the Study:

• To provide an updated overview of hormonal therapy options for low-grade endometrial stromal sarcoma.
• To discuss the evolving role of hormonal therapy in both treatment and recurrence prevention.

Main Methods:

• Review of current literature on hormonal therapies for LG-ESS.
• Analysis of treatment outcomes with progestins, aromatase inhibitors, and gonadotropin-releasing hormone analogues.

Main Results:

• Hormonal therapy, including progestins, aromatase inhibitors, and GnRH analogues, is an effective alternative to traditional treatments like radiation and chemotherapy.
• Aromatase inhibitors and GnRH analogues are emerging as preferred first and second-line treatments.
• Estrogen-containing therapies and tamoxifen are contraindicated due to potential growth stimulation and increased recurrence risk.
• Preventive hormonal therapy is a new development, with aromatase inhibitors showing promise, though optimal duration is undetermined.
• Progestins may have significant side effects, making aromatase inhibitors a more tolerated option.

Conclusions:

• Hormonal therapy represents a significant advancement in managing LG-ESS, offering an effective alternative to conventional treatments.
• Preventive hormonal therapy is particularly relevant for patients with co-existing endometriosis.
• Further research is needed to determine the optimal duration of preventive hormonal therapy.